SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJL. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000 [abstract]. BMC Cancer. 2002; 2: 37.
  • 2
    Kelly K, Crowley J, Bunn PA, et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001; 19: 32103218.
  • 3
    Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002; 20: 42854291.
  • 4
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 5
    Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet. 2003; 4: 937947.
  • 6
    Marsh S, McLeod HL. Cancer pharmacogenetics. Br J Cancer. 2004; 90: 811.
  • 7
    Brabec V, Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Update. 2002; 5(3–4): 147161.
  • 8
    Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001; 478(1–2): 2343.
  • 9
    Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res. 2001; 478(1–2): 121.
  • 10
    Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002; 62: 48994902.
  • 11
    Araujo SJ, Tirode F, Coin F, et al. Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Dev. 2000; 14: 349359.
  • 12
    Evans E, Moggs JG, Hwang JR, Egly JM, Wood RD. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J. 1997; 16: 65596573.
  • 13
    Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum Group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001; 61: 86548658.
  • 14
    Taron M, Alberola V, Sanchez J, et al. Transcription coupled repair, XPD and RRM1 gene polymorphisms predict gemcitabine/cisplatin outcome in NSCLC [abstract 2579]. Proc Am Soc Clin Oncol. 2003; 22.
  • 15
    Reguart N, Roig B, Vinyola S, et al. XPD polymorphisms in cisplatin/vinorelbine treated Stage IV NSCLC patients: genetic analysis of a Spanish Lung Cancer Group Phase II trial [abstract 3528]. Proc Am Soc Clin Oncol. 2003; 22: 877.
  • 16
    Sarries C, Alberola V, Mendez P, et al. Single nucleotide polymorphisms in DNA repair genes predicts survival in gemcitabine/cisplatin treated NSCLC patients [abstract 3450]. Proc Am Soc Clin Oncol. 2003; 22: 859.
  • 17
    Wei Q, Wang X, Shen H. DNA repair gene XPD polymorphism and lung cancer risk: a meta-analysis. Lung Cancer. 2004; 46: 110.
  • 18
    Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997; 111: 17101717.
  • 19
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205216.
  • 20
    Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 2001; 61: 13541357.
  • 21
    Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res. 1997; 25: 27452751.
  • 22
    Gordon D, Abajian C, Green P. Consed: a graphical tool for sequence finishing. Genome Res. 1998; 8: 195202.
  • 23
    Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using Phred. I. Accuracy assessment. Genome Res. 1998; 8: 175185.
  • 24
    Ewing B, Green P. Base-calling of automated sequencer traces using Phred. II. Error probabilities. Genome Res. 1998; 8: 186194.
  • 25
    Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001; 409: 928933.
  • 26
    Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet. 2001; 2: 930942.
  • 27
    Kwok PY. Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics Hum Genet. 2001; 2: 235258.
  • 28
    Park DJ, Stoehlmacher J, Zhang W, et al. XPD polymorphism is associated with clinical outcome in advanced colorectal cancer patients treated with 5-FU/oxaliplatin chemotherapy [abstract 534]. Proc Am Soc Clin Oncol. 2002; 21.
  • 29
    Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer. 2004; 91: 344354.
  • 30
    Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004; 22: 25192521.
  • 31
    Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer. 2004; 44: 311316.